New Avenues for Optimal Treatment of Atrial Fibrillation and Stroke Prevention.
Publisher DOI
PubMed ID
33626906
Abstract
One in 3 individuals free of atrial fibrillation (AF) at index age 55 years is estimated to develop AF later in life. AF increases not only the risk of ischemic stroke but also of dementia, even in stroke-free patients. In this review, we address recent advances in the heart-brain interaction with focus on AF. Issues discussed are (1) the timing of direct oral anticoagulants start following an ischemic stroke; (2) the comparison of direct oral anticoagulants versus vitamin K antagonists in early secondary stroke prevention; (3) harms of bridging with heparin before direct oral anticoagulants; (4) importance of appropriate direct oral anticoagulants dosing; (5) screening for AF in high-risk populations, including the role of wearables; (6) left atrial appendage occlusion as an alternative to oral anticoagulation; (7) the role of early rhythm-control therapy; (8) effect of lifestyle interventions on AF; (9) AF as a risk factor for dementia. An interdisciplinary approach seems appropriate to address the complex challenges posed by AF.
Date Issued
2021-04
Publication Type
Article
Subject(s)
Subjects
anticoagulant atrial appendage atrial fibrillation dementia hemorrhage
Language(s)
en
Author(s)
De Marchis, Gian Marco | |
Sposato, Luciano A | |
Kühne, Michael | |
Dittrich, Tolga D | |
Bonati, Leo H | |
Chaturvedi, Seemant |
Additional Credits
Journal
Stroke
Publisher
American Heart Association
ISSN
1524-4628
Access(Rights)
restricted